Develops gene therapies for severe neurological diseases.
Voyager Therapeutics, Inc. is a pioneering gene therapy company dedicated to advancing transformative treatments and cutting-edge platform technologies. At the forefront of its innovation is VY-AADC, the company's leading clinical candidate currently undergoing an open-label Phase 1 clinical trial for Parkinson's disease. This therapy aims to address critical unmet needs in neurodegenerative disorders by leveraging adeno-associated virus (AAV) gene therapy to deliver therapeutic genes directly to affected areas of the brain.
In addition to VY-AADC, Voyager Therapeutics boasts a robust pipeline of preclinical programs targeting various neurological conditions. These include VY-SOD102 for amyotrophic lateral sclerosis (ALS), VY-HTT01 for Huntington's disease, and VY-FXN01 for Friedreich's ataxia. The company's Tau program is also noteworthy, focusing on tauopathies such as Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as spinal muscular atrophy. Each program underscores Voyager's commitment to pioneering gene therapies that address complex neurological disorders.
Founded in 2013 and headquartered in Cambridge, Massachusetts, Voyager Therapeutics collaborates extensively within the biopharmaceutical industry. Partnerships with leading entities like Neurocrine Biosciences, Pfizer Inc., and Novartis Pharma AG further enhance its research, development, and commercialization efforts in AAV gene therapy products. These collaborations amplify Voyager's capacity to accelerate groundbreaking treatments and bring hope to patients globally.
With a steadfast dedication to scientific innovation and therapeutic advancement, Voyager Therapeutics continues to push the boundaries of gene therapy. Through its strategic partnerships and pioneering research initiatives, the company remains at the forefront of developing transformative therapies that hold promise for patients with debilitating neurological diseases.